NO330550B1 - Anvendelse av NMDA-affinitetsantagonist som antidepressiva - Google Patents
Anvendelse av NMDA-affinitetsantagonist som antidepressiva Download PDFInfo
- Publication number
- NO330550B1 NO330550B1 NO20014345A NO20014345A NO330550B1 NO 330550 B1 NO330550 B1 NO 330550B1 NO 20014345 A NO20014345 A NO 20014345A NO 20014345 A NO20014345 A NO 20014345A NO 330550 B1 NO330550 B1 NO 330550B1
- Authority
- NO
- Norway
- Prior art keywords
- ethanamine
- pyridyl
- phenyl
- nmda
- test
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title description 7
- 229940005513 antidepressants Drugs 0.000 title description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 6
- 239000005557 antagonist Substances 0.000 title description 5
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 claims description 15
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000020401 Depressive disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000012048 forced swim test Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KHJHFYAGQZYCLC-GXKRWWSZSA-N (1s)-1-phenyl-2-pyridin-2-ylethanamine;dihydrochloride Chemical compound Cl.Cl.C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 KHJHFYAGQZYCLC-GXKRWWSZSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901077A SE9901077D0 (sv) | 1999-03-23 | 1999-03-23 | Novel use |
| PCT/SE2000/000540 WO2000056324A1 (en) | 1999-03-23 | 2000-03-21 | The use of certain affinity nmda antagonists as antidepressants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20014345D0 NO20014345D0 (no) | 2001-09-06 |
| NO20014345L NO20014345L (no) | 2001-09-06 |
| NO330550B1 true NO330550B1 (no) | 2011-05-16 |
Family
ID=20414989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20014345A NO330550B1 (no) | 1999-03-23 | 2001-09-06 | Anvendelse av NMDA-affinitetsantagonist som antidepressiva |
| NO20101069A NO20101069L (no) | 1999-03-23 | 2010-07-27 | Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20101069A NO20101069L (no) | 1999-03-23 | 2010-07-27 | Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6479553B1 (ja) |
| EP (1) | EP1162967A1 (ja) |
| JP (1) | JP4705717B2 (ja) |
| KR (1) | KR20010108368A (ja) |
| CN (1) | CN1160065C (ja) |
| AR (1) | AR029343A1 (ja) |
| AU (1) | AU774117B2 (ja) |
| BR (1) | BR0009225A (ja) |
| CA (1) | CA2359568A1 (ja) |
| IL (1) | IL145334A0 (ja) |
| MX (1) | MXPA01009448A (ja) |
| MY (1) | MY135916A (ja) |
| NO (2) | NO330550B1 (ja) |
| NZ (1) | NZ513148A (ja) |
| SE (1) | SE9901077D0 (ja) |
| WO (1) | WO2000056324A1 (ja) |
| ZA (1) | ZA200106859B (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| AU2004251636B2 (en) * | 2003-05-27 | 2006-11-09 | Merz Pharma Gmbh & Co. Kgaa | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
| EP1761784B1 (en) * | 2004-05-24 | 2016-10-26 | Universität Zu Köln | Identification of ergothioneine transporter and therapeutic uses thereof |
| WO2006009769A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| CA2568445C (en) | 2004-06-17 | 2011-05-24 | Merz Pharma Gmbh & Co. Kgaa | Immediate release formulations of memantine oral dosage forms |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| CA2604052C (en) | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
| AU2006259619A1 (en) * | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
| WO2008005534A2 (en) * | 2006-07-06 | 2008-01-10 | Forest Laboratories, Inc. | Orally dissolving formulations of memantine |
| WO2009151498A2 (en) * | 2008-03-28 | 2009-12-17 | Forest Laboratories Holdings Limited | Memantine formulations |
| EP2138173A1 (en) | 2008-06-26 | 2009-12-30 | Merz Pharma GmbH & Co.KGaA | Pharmaceutical compositions comprising aminoadamantane derivatives |
| MX2011006680A (es) * | 2008-12-24 | 2011-07-12 | Astrazeneca Ab | Compuestos etanaminicos y su uso para tratar la depresion. |
| MX365650B (es) | 2009-12-02 | 2019-06-10 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
| CN104114714A (zh) * | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| EP3066091B1 (en) | 2013-11-05 | 2019-04-03 | Astrazeneca AB | Nmda antagonist prodrugs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84305A (en) * | 1987-02-06 | 1992-01-15 | Fisons Corp | 2-aminoacetamide derivatives |
| US5206248A (en) * | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| CA2133427C (en) * | 1992-04-03 | 2003-06-10 | Ronald Conrad Griffith | Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders |
| DE69809827D1 (de) * | 1997-03-31 | 2003-01-16 | Korea Res Inst Chem Tech | Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung |
-
1999
- 1999-03-23 SE SE9901077A patent/SE9901077D0/xx unknown
-
2000
- 2000-03-21 CA CA002359568A patent/CA2359568A1/en not_active Abandoned
- 2000-03-21 CN CNB008051771A patent/CN1160065C/zh not_active Expired - Lifetime
- 2000-03-21 US US09/554,315 patent/US6479553B1/en not_active Expired - Lifetime
- 2000-03-21 IL IL14533400A patent/IL145334A0/xx unknown
- 2000-03-21 WO PCT/SE2000/000540 patent/WO2000056324A1/en not_active Application Discontinuation
- 2000-03-21 NZ NZ513148A patent/NZ513148A/en not_active IP Right Cessation
- 2000-03-21 MY MYPI20001108A patent/MY135916A/en unknown
- 2000-03-21 MX MXPA01009448A patent/MXPA01009448A/es unknown
- 2000-03-21 KR KR1020017012075A patent/KR20010108368A/ko not_active Application Discontinuation
- 2000-03-21 EP EP00921221A patent/EP1162967A1/en not_active Withdrawn
- 2000-03-21 BR BR0009225-8A patent/BR0009225A/pt not_active Application Discontinuation
- 2000-03-21 AU AU41561/00A patent/AU774117B2/en not_active Expired
- 2000-03-21 JP JP2000606229A patent/JP4705717B2/ja not_active Expired - Lifetime
- 2000-03-22 AR ARP000101292A patent/AR029343A1/es not_active Application Discontinuation
-
2001
- 2001-08-20 ZA ZA200106859A patent/ZA200106859B/en unknown
- 2001-09-06 NO NO20014345A patent/NO330550B1/no not_active IP Right Cessation
-
2010
- 2010-07-27 NO NO20101069A patent/NO20101069L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE9901077D0 (sv) | 1999-03-23 |
| BR0009225A (pt) | 2001-12-26 |
| US6479553B1 (en) | 2002-11-12 |
| WO2000056324A1 (en) | 2000-09-28 |
| KR20010108368A (ko) | 2001-12-07 |
| ZA200106859B (en) | 2002-11-20 |
| CN1160065C (zh) | 2004-08-04 |
| MY135916A (en) | 2008-07-31 |
| NO20014345D0 (no) | 2001-09-06 |
| NZ513148A (en) | 2003-10-31 |
| MXPA01009448A (es) | 2002-08-06 |
| AU4156100A (en) | 2000-10-09 |
| AR029343A1 (es) | 2003-06-25 |
| CN1344157A (zh) | 2002-04-10 |
| NO20101069L (no) | 2001-09-06 |
| JP4705717B2 (ja) | 2011-06-22 |
| EP1162967A1 (en) | 2001-12-19 |
| IL145334A0 (en) | 2002-06-30 |
| JP2002539256A (ja) | 2002-11-19 |
| CA2359568A1 (en) | 2000-09-28 |
| NO20014345L (no) | 2001-09-06 |
| AU774117B2 (en) | 2004-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330550B1 (no) | Anvendelse av NMDA-affinitetsantagonist som antidepressiva | |
| RU2221563C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона | |
| AU761510B2 (en) | Combination therapy for treatment of refractory depression | |
| US20090068290A1 (en) | Bifeprunox doses for treating schizophrenia | |
| AU2006231752B2 (en) | Preventive or remedy for depression or anxiety neurosis | |
| US6335371B1 (en) | Method for inducing cognition enhancement | |
| WO2008025780A1 (en) | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein | |
| WO2020208564A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| EP1420782B1 (en) | Use of nefiracetam for treating post-stroke neurodegeneration | |
| EP1171123B1 (en) | Method for treating neurodegeneration | |
| MXPA01010340A (es) | Osanetant en el tratamiento de transtornos del humor. | |
| JP2004537548A (ja) | 認知機能の減衰及び／又は損傷を治療するための医薬組成物 | |
| CN114917213B (zh) | 包含阿米替林的精神疾病治疗剂和治疗精神疾病的方法 | |
| RU2775772C2 (ru) | Норадренергический и специфически серотонинергический анксиолитик и антидепрессант, способ его получения и применения | |
| JPWO2004096230A1 (ja) | 関節リウマチ治療剤 | |
| CN105061217A (zh) | 枸橼酸舍曲林的2种晶型及其制备方法 | |
| WO2020240489A1 (en) | Selective histamine h3 receptor antagonists for treating autism spectrum disorder | |
| EA047671B1 (ru) | Новая кристаллическая форма 7-бром-1-(гидразинокарбонил)метил-5-фенил-1,2-дигидро-3h-1,4-бензодиазепин-2-она и ее фармацевтическое применение | |
| WO2009136176A1 (en) | Compositions and methods for the treatment of fibromyalgia | |
| AU3449493A (en) | Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses | |
| Krueger et al. | Lorcaserin (belviq): serotonin 2C receptor agonist for the treatment of obesity | |
| WO2002043727A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |